Preclinical Studies Of Group A Streptococcal Vaccine Candidates
Funder
National Health and Medical Research Council
Funding Amount
$532,492.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
RV3 Rotavirus Vaccine: Developing A Neonatal Rotavirus Vaccine Formulation For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$135,075.00
Summary
Rotavirus infection is the leading cause of severe dehydrating gastroenteritis responsible for approximately 600,000 deaths per year in children under 5 years of age worldwide. There is a commercial and public health opportunity to develop a new rotavirus vaccine that can be given at birth. By modifying the way the vaccine is made we hope that it will be more acceptable and easily delivered to children in remote communities and developing countries without the need for refrigeration.